Featured Publications
Association of iron infusion reactions with ABO blood type
Butt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type. European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.Peer-Reviewed Original ResearchConceptsGreater oddsBlood typeYale Cancer CenterInfusion-related reactionsRetrospective chart reviewLarger patient numbersABO blood typeType AB bloodChart reviewInfusion reactionsMost patientsHematology clinicIron sucroseMultivariable analysisProspective studyCancer CenterPatient numbersIron dextranRisk factorsIron infusionIron repletionPatientsPossible associationAB bloodBlood
2024
Associations between patient characteristics and progression to multiple myeloma among patients with monoclonal gammopathy of undetermined significance: A systematic review
Li Y, Hsu S, Wang R, Theprungsirikul P, Neparidze N, Chang S, Wang S. Associations between patient characteristics and progression to multiple myeloma among patients with monoclonal gammopathy of undetermined significance: A systematic review. Clinical Lymphoma Myeloma & Leukemia 2024 DOI: 10.1016/j.clml.2024.12.006.Peer-Reviewed Original ResearchProgression to MMMultiple myelomaNewcastle-Ottawa ScaleMonoclonal gammopathyRisk of progression to MMIncreased riskProgression to multiple myelomaRisk estimatesHigher body mass indexPre-malignant conditionBody mass indexRandom-effects modelMass indexCohort studyPatient characteristicsFemale sexMale genderMethodological qualityNewcastle-OttawaBlack raceRisk ratioMGUSRisk factorsPublication biasSystematic review
2023
CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.Peer-Reviewed Original ResearchCytokine release syndromeDiffuse large B-cell lymphomaCAR T-cell therapyCAR T-cell productsCAR-T productsNon-Hodgkin lymphomaBest cutoff pointMultiple myelomaHigher oddsDay 3Risk factorsTime pointsCutoff pointDay 5Day 0Median absolute lymphocyte countChimeric antigen receptor T cellsRefractory non-Hodgkin lymphomaCAR T-cell infusionAntigen receptor T cellsLarge B-cell lymphomaCAR-T activationFludarabine/cyclophosphamideHigher baseline CRPPossible inflammatory mediators
2021
Iron Infusion Reactions: Risk Factors and Real-World Experience
Butt A, Muradashvili T, Soliman S, Goshua G, Burns A, Bar N, Martin K, Borgman G, Bona R, Lee A, Neparidze N. Iron Infusion Reactions: Risk Factors and Real-World Experience. Blood 2021, 138: 4154. DOI: 10.1182/blood-2021-151048.Peer-Reviewed Original ResearchInfusion-related reactionsSeverity of IRRsHistory of CVDHistory of allergyCardiovascular diseaseBeta blockersOral ironPatient characteristicsRisk factorsLower oddsGreater oddsExact testAngiotensin-converting enzyme inhibitor useAssociation of CVDYale-New Haven HospitalEnzyme inhibitor useFirst-line therapyHeavy menstrual bleedingRetrospective chart reviewMajority of patientsAnti-inflammatory effectsMajor adverse effectsIron deficiency anemiaMultivariable regression analysisSeverity of reactions